Oxygenta Pharmaceutical Reports Q2 FY27 Results with Revenue Growth and Narrowing Net Loss
Oxygenta Pharmaceutical Ltd · Financial Result · 10 Nov 2026, 10:29 pm
Oxygenta Pharmaceutical Reports Q2 FY27 Results with Revenue Growth and Narrowing Net Loss Oxygenta Pharmaceutical reported revenue from operations of ₹3,349.39 lakhs for the quarter ended 30th Sep'26, up 134.18% YoY from ₹1,430.23 lakhs, though down 9.47% QoQ. Total expenses stood at ₹3,690.96 lakhs, leading to a loss before tax of ₹339.54 lakhs compared to a loss of ₹643.78 lakhs in Q2 FY26. Net loss narrowed YoY to ₹273.53 lakhs from ₹493.04 lakhs. Diluted EPS improved to ₹(0.74) versus ₹(1.33) YoY. For H1 FY27, revenue reached ₹7,049.09 lakhs with a net loss of ₹483.90 lakhs.
Original exchange filing (PDF)
More announcements from Oxygenta Pharmaceutical Ltd
- Outcome of Board Meeting held on Tuesday i.e. 10th November, 2026. · 10 Nov 2026
- Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2026 ,inter alia, to consider and approve 1. Un-audited Financial .... · 10 Nov 2026
- Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015. · 01 Oct 2026
- Disclosure under Regulation 44(3) of SEBI (LODR), Regulations, 2015. · 21 Aug 2026
- Outcome of 33rd Annual General Meeting held on 21.08.2026. · 21 Aug 2026
- Newspaper Advertisement for Notice of AGM scheduled to be held on 21st August, 2026. · 31 Jul 2026
- Intimation of Book Closure and Cut-off Date for the AGM · 30 Jul 2026
- Submission of 33rd Annual Report for the Financial Year 2025-26 under Regulation 34 of SEBI (LODR), Regulations, 2015 · 30 Jul 2026
